Cargando…
Innate Immune Receptors, Key Actors in Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system frequently results in ma...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393405/ https://www.ncbi.nlm.nih.gov/pubmed/32760860 http://dx.doi.org/10.1016/j.jacbts.2020.03.015 |
_version_ | 1783565038228865024 |
---|---|
author | Jaén, Rafael I. Val-Blasco, Almudena Prieto, Patricia Gil-Fernández, Marta Smani, Tarik López-Sendón, José Luis Delgado, Carmen Boscá, Lisardo Fernández-Velasco, María |
author_facet | Jaén, Rafael I. Val-Blasco, Almudena Prieto, Patricia Gil-Fernández, Marta Smani, Tarik López-Sendón, José Luis Delgado, Carmen Boscá, Lisardo Fernández-Velasco, María |
author_sort | Jaén, Rafael I. |
collection | PubMed |
description | Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system frequently results in maladaptive inflammatory responses that promote cardiovascular dysfunction and remodeling. Much research has focused on determining whether some mediators of the innate immune system are potential targets for CVD therapy. The innate immune system has specific receptors—termed pattern recognition receptors (PRRs)—that not only recognize pathogen-associated molecular patterns, but also sense danger-associated molecular signals. Activation of PRRs triggers the inflammatory response in different physiological systems, including the cardiovascular system. The classic PRRs, toll-like receptors (TLRs), and the more recently discovered nucleotide-binding oligomerization domain-like receptors (NLRs), have been recently proposed as key partners in the progression of several CVDs (e.g., atherosclerosis and heart failure). The present review discusses the key findings related to the involvement of TLRs and NLRs in the progression of several vascular and cardiac diseases, with a focus on whether some NLR subtypes (nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing receptor 3 and nucleotide-binding oligomerization domain-containing protein 1) can be candidates for the development of new therapeutic strategies for several CVDs. |
format | Online Article Text |
id | pubmed-7393405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73934052020-08-04 Innate Immune Receptors, Key Actors in Cardiovascular Diseases Jaén, Rafael I. Val-Blasco, Almudena Prieto, Patricia Gil-Fernández, Marta Smani, Tarik López-Sendón, José Luis Delgado, Carmen Boscá, Lisardo Fernández-Velasco, María JACC Basic Transl Sci STATE-OF-THE-ART REVIEW Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system frequently results in maladaptive inflammatory responses that promote cardiovascular dysfunction and remodeling. Much research has focused on determining whether some mediators of the innate immune system are potential targets for CVD therapy. The innate immune system has specific receptors—termed pattern recognition receptors (PRRs)—that not only recognize pathogen-associated molecular patterns, but also sense danger-associated molecular signals. Activation of PRRs triggers the inflammatory response in different physiological systems, including the cardiovascular system. The classic PRRs, toll-like receptors (TLRs), and the more recently discovered nucleotide-binding oligomerization domain-like receptors (NLRs), have been recently proposed as key partners in the progression of several CVDs (e.g., atherosclerosis and heart failure). The present review discusses the key findings related to the involvement of TLRs and NLRs in the progression of several vascular and cardiac diseases, with a focus on whether some NLR subtypes (nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing receptor 3 and nucleotide-binding oligomerization domain-containing protein 1) can be candidates for the development of new therapeutic strategies for several CVDs. Elsevier 2020-07-27 /pmc/articles/PMC7393405/ /pubmed/32760860 http://dx.doi.org/10.1016/j.jacbts.2020.03.015 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | STATE-OF-THE-ART REVIEW Jaén, Rafael I. Val-Blasco, Almudena Prieto, Patricia Gil-Fernández, Marta Smani, Tarik López-Sendón, José Luis Delgado, Carmen Boscá, Lisardo Fernández-Velasco, María Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title | Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title_full | Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title_fullStr | Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title_full_unstemmed | Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title_short | Innate Immune Receptors, Key Actors in Cardiovascular Diseases |
title_sort | innate immune receptors, key actors in cardiovascular diseases |
topic | STATE-OF-THE-ART REVIEW |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393405/ https://www.ncbi.nlm.nih.gov/pubmed/32760860 http://dx.doi.org/10.1016/j.jacbts.2020.03.015 |
work_keys_str_mv | AT jaenrafaeli innateimmunereceptorskeyactorsincardiovasculardiseases AT valblascoalmudena innateimmunereceptorskeyactorsincardiovasculardiseases AT prietopatricia innateimmunereceptorskeyactorsincardiovasculardiseases AT gilfernandezmarta innateimmunereceptorskeyactorsincardiovasculardiseases AT smanitarik innateimmunereceptorskeyactorsincardiovasculardiseases AT lopezsendonjoseluis innateimmunereceptorskeyactorsincardiovasculardiseases AT delgadocarmen innateimmunereceptorskeyactorsincardiovasculardiseases AT boscalisardo innateimmunereceptorskeyactorsincardiovasculardiseases AT fernandezvelascomaria innateimmunereceptorskeyactorsincardiovasculardiseases |